SCHEMBL7721972

SCHEMBL7721972

CCc1nc2c(C(=O)OC)cccc2o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 2/20 0.55
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
RIPK1 Q13546 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
ATM Q13315 2/20 0.43
GAA P10253 1/20 0.43
PKN1 Q16512 1/20 0.40
PKN2 Q16513 1/20 0.40
PTGES O14684 1/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9178689 0.87 TOP2A (0.54) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL4307487 0.87 TOP2A (0.54) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL27379841 0.87 TOP2A (0.51) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL4303871 0.85 TOP2A (0.50) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL7721868 0.84 MAOB (0.46) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL30445192 0.84 MAOB (0.46) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL1271524 0.81 SMN1; SMN2 (0.49) TOP2AKMT2AKDM4EALDH1A1HPGD
SCHEMBL1398896 0.81 TOP2A (0.59) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL1005317 0.81 HTR3A (0.54) TOP2ANPC1RAB9AKMT2AKDM4E
SCHEMBL7440762 0.80 TOP2A (0.55) TOP2ANPC1RAB9AKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951087-B2 Fused ring analogues of anti-fibrotic agents FIBROTECH THERAPEUTICS PTY LTD (AU) 2018-04-24 US disclosed
US-8426401-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV 2013-04-23 US disclosed
US-20100324011-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324011-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA TOP2A 1227/4885NPC1 187/4885RAB9A 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.